Elicio Therapeutics, INC 8-K filings

Elicio Therapeutics has successfully raised $20 million through a private placement of a senior secured convertible promissory note.

Elicio Therapeutics has announced the pricing of an $11.5 million underwritten public offering to fund its immunotherapy development pipeline and for general corporate purposes.

Elicio Therapeutics reported that patients receiving the Phase 2 dose of their cancer vaccine ELI-002 7P have not reached median disease-free survival in an ongoing Phase 1a study.

Elicio Therapeutics reported promising early data from its Phase 1a study of ELI-002 7P, showing strong T-cell responses and tumor biomarker reductions in patients with mKRAS-driven solid tumors.

Elicio Therapeutics announced progress in its clinical trials for the ELI-002 cancer vaccine, including positive Phase 1 data and the initiation of a Phase 2 trial, while also reporting increased R&D expenses and a net loss for the first quarter of 2024.

Elicio Therapeutics presented promising clinical data for ELI-002, showing strong T-cell responses and antigen spreading, and preclinical data for ELI-007 and ELI-008, demonstrating significantly enhanced immune responses compared to conventional vaccines.

Elicio Therapeutics reported its 2023 financial results, highlighted clinical trial progress, and announced a $6 million private placement.

Elicio Therapeutics has entered into a subscription agreement for a $6 million private placement of pre-funded warrants to advance its cancer immunotherapy pipeline.

Elicio Therapeutics has increased base salaries for its CEO and CSO, granted stock options, and implemented a new executive severance plan.

Elicio Therapeutics announced a poster presentation at the ASCO GI Symposium detailing the Phase 1/2 study design for their ELI-002 7P cancer vaccine targeting KRAS-mutated pancreatic cancer.

Elicio Therapeutics has generated approximately $4.89 million in net proceeds by selling 584,170 shares of its common stock through its at-the-market equity offering program since the end of the third quarter of 2023.